← Back to Search

Behavioural Intervention

reSET-O for Opioid Use Disorder

N/A
Waitlist Available
Research Sponsored by Pear Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Provide written informed consent prior to any study specific assessments being performed
Male or female ≥18 years of age, inclusive
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from week 1 to week 4
Awards & highlights

Study Summary

This trial will test a new digital therapy to help people start and stick with buprenorphine treatment for opioid addiction.

Eligible Conditions
  • Opioid Use Disorder

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are able to use common software applications on an internet-enabled mobile device (smart phone or tablet).
Select...
You are interested in testing or using PEAR-002b.
Select...
You have no prior history of use of reSET-O.
Select...
You have not participated in any other investigational drug trials within the past 30 days (or within 5 half-lives of study drug, whichever is longer) of enrollment.
Select...
You are able to understand and communicate in English.
Select...
You are currently using buprenorphine.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from week 1 to week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and from week 1 to week 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Buprenorphine Initiation Success
Medication Adherence Rates
PEAR-002B Qualitative User Experience Interviews
+1 more
Secondary outcome measures
PEAR-002B Engagement Data
reSET-O Qualitative User Experience Interviews
reSET-O User Satisfaction Surveys
Other outcome measures
Abstinence From Illicit Opioids
Device Wearing Time
Physiological Biomarker Data
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: PEAR-002B / reSET-OExperimental Treatment2 Interventions
Digital Therapeutic
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PEAR-002B
2022
N/A
~10
reSET-O
2022
N/A
~60

Find a Location

Who is running the clinical trial?

Whitman-Walker Institute, Inc.OTHER_GOV
Hassman Research Institute, LLCUNKNOWN
Pear Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
1,910 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Oregon
How old are they?
18 - 65
What site did they apply to?
Whitman-Walker, Inc
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Email
~3 spots leftby Mar 2025